Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Comparison of the degree and speed of virologic response to two treatment options in patients with chronic Hepatitis C.
Scientific title
Chronic hepatitis C virus genotype 4 infected patients treated with a either one of generic Sofosbuvir plus ribavirin for 3 months versus 6 months duration based on their very rapid or ultra rapid virologic response
Secondary ID [1] 287269 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
chronic hepatitis C 295889 0
Condition category
Condition code
Oral and Gastrointestinal 296140 296140 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Infection 296141 296141 0 0
Other infectious diseases

Study type
Description of intervention(s) / exposure
Group 1 started treatment with Gratisovir 400mg tablets (Sofosbuvir-Pharco), one tablet daily after main meal plus Weight-Based Dosing (WBD) of Hepaverin capsules (Ribavirin) 1200mg if body weight is 75kg or above and 1000 mg if body weight is <75 kg, twice daily, orally; patients who achieve very rapid Virologic response (i.e. undetectable hepatitis C virus RNA Levels at week 2) will be then randomized to receive treatment for a total duration of 3 months or 6 months. Patients who do not achieve the very rapid virologic response will be treated for a total duration of 6 months.
Intervention code [1] 292568 0
Treatment: Drugs
Comparator / control treatment
Group 2 started treatment with Grateziano 400mg tablets (Sofosbuvir-EEPI), one tablet daily after main meal plus Weight-Based Dosing (WBD) of Hepaverin capsules (Ribavirin) 1200mg if body weight is 75kg or above and 1000 mg if body weight is below 75 kg, twice daily, orally; for a duration of 6 or 3 months according to further randomization for those achieving vRVR.
Control group

Primary outcome [1] 295817 0
Sustained virologic response (serum HCV RNA below level of quantification at 12 weeks post treatment).
Timepoint [1] 295817 0
12 weeks after end of treatment
Primary outcome [2] 295818 0
very Rapid Virologic Response (vRVR) (i.e. Serum HCV RNA below level of quantification at the end of week 2 of therapy)
Timepoint [2] 295818 0
2 weeks after starting treatment
Primary outcome [3] 295819 0
ultra Rapid Virologic Response (i.e. serum HCV RNA below level of quantification or decreased by at least 4 Logs10 at the end of one week of therapy)
Timepoint [3] 295819 0
1 week after treatment start
Secondary outcome [1] 316595 0
Adverse drug reactions assessed clinically or by laboratory tests; examples of possible adverse reactions/events are: anemia, thrombocytopenia (assessed by complete blood count), headache, fatigue, abdominal pain, skin rash, itching (assessed clinically by symptoms and signs)
Timepoint [1] 316595 0
throughout the study, by weekly clinical evaluation, complete blood count, liver and function tests.

Key inclusion criteria
Chronic Hepatitis C genotype 4 infection with HCV RNA levels > 4 Log 10
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Other causes of chronic hepatitis such as hepatitis B or autoimmune hepatitis.
critically ill patients and severe organ dysfunctions

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The study is a randomized, open-label, comparative effectiveness study design.
Consecutive patients presenting to the outpatient clinics with chronic HCV were screened for eligibility. Those eligible were randomized centrally to 2 groups.
Allocation was carried out with the randomization centrally by patient sequent numbers and the allocation sequence kept in sealed opaque envelopes to be opened by investigators at day 0 just before starting treatment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomization was done using software generated balanced block randomization technique.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Those who experienced vRVR were further randomized to either 3 months treatment duration or 6 months duration
Phase 3 / Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 7089 0
State/province [1] 7089 0

Funding & Sponsors
Funding source category [1] 291826 0
Name [1] 291826 0
Abass Helmy Charity establishment
Address [1] 291826 0
186 Broadcast street (186 Al-Qawmia Arabia street), South tramway Bakkos, Bokkos province, Alexandria, 21616
Country [1] 291826 0
Primary sponsor type
Mostafa Yakoot
Green Clinic and Research Centre
27 Green Street, Alexandria, Egypt, 21121
Secondary sponsor category [1] 290489 0
Name [1] 290489 0
Address [1] 290489 0
Country [1] 290489 0
Other collaborator category [1] 278579 0
Name [1] 278579 0
Address [1] 278579 0
Country [1] 278579 0

Ethics approval
Ethics application status
Ethics committee name [1] 293345 0
GREEN CRC Ethics committee #1
Ethics committee address [1] 293345 0
27 Green Street, Alexandria 21121
Ethics committee country [1] 293345 0
Date submitted for ethics approval [1] 293345 0
Approval date [1] 293345 0
Ethics approval number [1] 293345 0

Brief summary
We designed this comparative effectiveness study as a quick economic model to timely support making an urgent choice for a cost/effective dual antiviral treatment protocol for chronic hepatitis C in a limited resource charity setting.
Methods: Data collected during the period of this interim report from the first 25 patients randomized to either one of two generic Sofosbuvir products (Grateziano or Gratisovir) in a daily dose of one 400 mg tablet plus a weight based ribavirin dose, were analyzed for both the degree and speed of virus load reduction at the end of 1 and 2 weeks from starting treatment.
As we planned to include a sample of 200 patients for a mean follow up duration of 9 months, the full report is expected to be available by the end of the year 2016.
Here we present interim data collected from the first 25 patients included in the study during the first 2 weeks of treatment.

The Log10 transformed virus load (Log PCR) in both groups showed an almost equal markedly significant reduction both at the end of week 1 and week 2 of starting treatment by more than 4 and 5 Logs respectively. The differences between the 2 treatment groups at both analysis points were not statistically significant (p = 602, 728) by both student t test and repeated measures ANOVA test.Whereas the difference between proportions of patients with ultra-rapid virologic response (uRVR) at the end of week 1 and very-rapid virologic response (vRVR) at the end of week 2 in both groups were also not statistically significant (vRVR: 10/13 versus 10/12 respectively (p = 0.95, 0.86 respectively))
Conclusion: We can conclude from this interim report that the two generic products Gratisovir and Grateziano are almost equally effective and equally rapid in reducing the HCV virus load. The predictive accuracy of our suggested markers of efficacy (the vRVR and the uRVR) and the results of truncated 3 months response guided therapy versus the recommended 6 months course duration will be addressed upon full completion of the study in our final report.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 59494 0
Dr Mostafa Yakoot
Address 59494 0
Green Clinic and Research Centre
27 Green Street, Alexandria city, post code 21121
Country 59494 0
Phone 59494 0
Fax 59494 0
Email 59494 0
Contact person for public queries
Name 59495 0
Dr Mostafa Yakoot
Address 59495 0
Green Clinic and Research Centre
27 Green Street, Alexandria city, post code 21121
Country 59495 0
Phone 59495 0
Fax 59495 0
Email 59495 0
Contact person for scientific queries
Name 59496 0
Dr Mostafa Yakoot
Address 59496 0
Green Clinic and Research Centre
27 Green Street, Alexandria city, post code 21121
Country 59496 0
Phone 59496 0
Fax 59496 0
Email 59496 0

No information has been provided regarding IPD availability
Summary results
No Results